Dr. Ruemu Birhiray explains chronic myeloid leukemia (CML), its treatment options, and what patients should know about this ...

Both dasatinib and nilotinib appear to have activity in CML patients with mutations within the abl kinase domain, including in the P-loop, A-loop and catalytic domains. Dasatinib and nilotinib ...

Here’s what the data revealed. The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at ...

Thus, identification of novel agents and the development of new strategies for the effective treatment of CML patients with the T315I mutation are important and challenging tasks. In this review ...

In the case of CML, some patients treated with imatinib acquire mutations in Bcr-Abl and ultimately progress to an acute phase of the disease. A combination of targeted agents and chemotherapy may ...

Many important clinical conditions like Down syndrome and chronic myelogenous leukemia result from translocation mutations. A change in chromosome structure and content caused by translocation ...

1 Among all evaluable patients with chronic-phase CML (CP-CML), the complete cytogenetic ... irrespective of the presence of the T315I mutation, which confers resistance against imatinib and ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, ...

The ASH Annual Meeting is one of the largest gatherings of the international hematology community, bringing together the most cutting-edge scientific research and latest data of investigational ...